IL182244A0 - Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer - Google Patents
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancerInfo
- Publication number
- IL182244A0 IL182244A0 IL182244A IL18224407A IL182244A0 IL 182244 A0 IL182244 A0 IL 182244A0 IL 182244 A IL182244 A IL 182244A IL 18224407 A IL18224407 A IL 18224407A IL 182244 A0 IL182244 A0 IL 182244A0
- Authority
- IL
- Israel
- Prior art keywords
- ctla
- antibody
- breast cancer
- combination treatment
- aromatase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62485604P | 2004-11-04 | 2004-11-04 | |
| PCT/IB2005/003307 WO2006048749A1 (en) | 2004-11-04 | 2005-10-24 | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL182244A0 true IL182244A0 (en) | 2007-09-20 |
Family
ID=35825412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL182244A IL182244A0 (en) | 2004-11-04 | 2007-03-27 | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1819735A1 (en) |
| JP (1) | JP2008518902A (en) |
| KR (1) | KR20070067702A (en) |
| CN (1) | CN101052655A (en) |
| AR (1) | AR053651A1 (en) |
| AU (1) | AU2005300315A1 (en) |
| BR (1) | BRPI0515735A2 (en) |
| CA (1) | CA2586844A1 (en) |
| IL (1) | IL182244A0 (en) |
| MX (1) | MX2007003804A (en) |
| NO (1) | NO20072576L (en) |
| RU (1) | RU2007114111A (en) |
| TW (1) | TW200621804A (en) |
| WO (1) | WO2006048749A1 (en) |
| ZA (1) | ZA200702577B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006114702A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| EP1904530A2 (en) * | 2005-07-07 | 2008-04-02 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8449886B2 (en) | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| CN102227501B (en) | 2008-09-26 | 2016-11-16 | 托卡根公司 | Gene therapy vector and cytosine deaminase |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| EP2344540B1 (en) | 2008-10-02 | 2017-11-29 | Aptevo Research and Development LLC | Cd86 antagonist multi-target binding proteins |
| PL2769737T3 (en) * | 2009-07-20 | 2017-08-31 | Bristol-Myers Squibb Company | Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| CN103945902B (en) | 2011-08-30 | 2018-07-20 | 阿斯泰克斯制药公司 | Decitabine derivative formulations |
| PE20142363A1 (en) * | 2011-10-14 | 2015-01-30 | Genentech Inc | USES AND MANUFACTURING ARTICLE INCLUDING HER2 PERTUZUMAB DIMERIZATION INHIBITOR |
| PT2844282T (en) | 2012-05-04 | 2019-07-23 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| CN103768596B (en) * | 2012-10-17 | 2016-06-22 | 苏州丁孚靶点生物技术有限公司 | For the combination product of oncotherapy, its purposes and correlation technique |
| ES2786051T3 (en) | 2012-10-25 | 2020-10-08 | Tocagen Inc | Retroviral vector with mini-promoter cassette |
| PT2961388T (en) | 2013-03-01 | 2019-07-11 | Astex Pharmaceuticals Inc | Drug combinations |
| EP3057990B1 (en) * | 2013-10-18 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| AU2016287585B2 (en) | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| WO2017040815A1 (en) | 2015-09-04 | 2017-03-09 | Tocagen Inc. | Recombinant vectors comprising 2a peptide |
| CN106883298B (en) | 2015-12-16 | 2021-12-17 | 上海康岱生物医药技术股份有限公司 | Bispecific conjugated antibodies, methods of making and uses thereof |
| BR112018013930A2 (en) | 2016-01-08 | 2018-12-11 | Replimune Limited | oncolytic virus, virus expressing three heterologous genes, pharmaceutical composition, virus for use, manufacturing product, cancer treatment method, and virus use |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
| CN109906088A (en) * | 2016-08-26 | 2019-06-18 | 奥野哲治 | Microvascular blood flow reduces agent and its application |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CN114984206A (en) | 2017-03-02 | 2022-09-02 | 基因泰克公司 | Adjunctive treatment for HER2 positive breast cancer |
| WO2018167780A1 (en) * | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| JP2020529409A (en) | 2017-08-03 | 2020-10-08 | 大塚製薬株式会社 | Drug compounds and their purification methods |
| US20230113802A1 (en) * | 2020-02-27 | 2023-04-13 | University Of Washington | Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
-
2005
- 2005-10-24 BR BRPI0515735-8A patent/BRPI0515735A2/en not_active IP Right Cessation
- 2005-10-24 CN CNA2005800377929A patent/CN101052655A/en active Pending
- 2005-10-24 AU AU2005300315A patent/AU2005300315A1/en not_active Abandoned
- 2005-10-24 CA CA002586844A patent/CA2586844A1/en not_active Abandoned
- 2005-10-24 MX MX2007003804A patent/MX2007003804A/en unknown
- 2005-10-24 JP JP2007538539A patent/JP2008518902A/en not_active Withdrawn
- 2005-10-24 KR KR1020077010096A patent/KR20070067702A/en not_active Application Discontinuation
- 2005-10-24 WO PCT/IB2005/003307 patent/WO2006048749A1/en active Application Filing
- 2005-10-24 RU RU2007114111/13A patent/RU2007114111A/en unknown
- 2005-10-24 EP EP05798369A patent/EP1819735A1/en not_active Ceased
- 2005-11-01 TW TW094138271A patent/TW200621804A/en unknown
- 2005-11-02 AR ARP050104588A patent/AR053651A1/en not_active Application Discontinuation
-
2007
- 2007-03-27 IL IL182244A patent/IL182244A0/en unknown
- 2007-03-28 ZA ZA200702577A patent/ZA200702577B/en unknown
- 2007-05-21 NO NO20072576A patent/NO20072576L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008518902A (en) | 2008-06-05 |
| ZA200702577B (en) | 2008-07-30 |
| TW200621804A (en) | 2006-07-01 |
| KR20070067702A (en) | 2007-06-28 |
| EP1819735A1 (en) | 2007-08-22 |
| BRPI0515735A2 (en) | 2011-10-11 |
| AU2005300315A1 (en) | 2006-05-11 |
| CN101052655A (en) | 2007-10-10 |
| NO20072576L (en) | 2007-08-03 |
| WO2006048749A1 (en) | 2006-05-11 |
| RU2007114111A (en) | 2008-12-10 |
| CA2586844A1 (en) | 2006-05-11 |
| MX2007003804A (en) | 2007-04-23 |
| AR053651A1 (en) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL182244A0 (en) | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer | |
| HRP20181565T1 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
| PL1874821T3 (en) | Combination of antibodies and glucocorticoids for treating cancer | |
| EP1793858A4 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
| PT1611890E (en) | Methods for assessing and treating cancer | |
| EP1741449A4 (en) | Preventive and/or remedy for cancer |